Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...